MAIAHealthcare · Biotechnology

MAIA Stock Forecast: MAIA Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$1.39

+0.72% on the day

The 1 Wall Street analysts covering MAIA Biotechnology, Inc. hold a median 12-month price target of $12 — +763.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$84.5M

Ticker Nerd rank

20 / 100

Median analyst target

$12

Analysts covering

Total return, dividends reinvested

−0.7%

+4.5%

YTD

−9.2%

From 52W high

−52.9%

From 52W low

+59.6%

$0.87

$2.95

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MAIA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MAIA Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Value

Accruals

Quality

Volatility

Momentum

Revisions

Issuance

Growth

Size (77): Smaller than most of the companies we track.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MAIA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MAIA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $10Median $12High $14

The green dot is the last close — the median target sits +763.3% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
21 Feb 2023	Noble Capital Markets	Initiates	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MAIA appears on the weeks it earns a place.

Estimates

MAIA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

MAIA Biotechnology, Inc. (MAIA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −2.0×
Price / sales: —
Price / book: 4.1×
EV / EBITDA: −2.4×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −218.7%
Return on assets: −92.1%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MAIA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
MAIAMAIA Biotechnology, Inc.	$84.5M	20
DWTXDogwood Therapeutics, Inc.	$84.6M	37
ELOXEloxx Pharmaceuticals, Inc.	$84.7M	15
GANXGain Therapeutics, Inc.	$84.7M	29
VRCAVerrica Pharmaceuticals, Inc.	$82.8M	73
KLRSKalaris Therapeutics, Inc.	$87.0M	22
ACETAdicet Bio, Inc.	$88.0M	43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MAIA Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MAIA news & analysis

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

GlobeNewsWire · 17 Aug 2026neutral

Diamond Equity Research released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary comes from a report commissioned by MAIA Biotechnology and produced by Diamond Equity Research, a firm focused on small-cap public companies.

Why it matters — MAIA watchers may find the update note a useful source of third-party research coverage on the company's progress.

FAQ

Frequently asked questions about MAIA stock

What is the MAIA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering MAIA Biotechnology, Inc. have a median 12-month price target of $12, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MAIA stock a buy right now?

Of the 1 analysts covering MAIA Biotechnology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MAIA Biotechnology, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MAIA?

As at 22 Aug 2026, MAIA Biotechnology, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (77 of 100).

Will MAIA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +763.3% from the last close, and Ticker Nerd's factor model ranks MAIA Biotechnology, Inc. 20 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MAIA stock forecast for 2030?

No analyst covering MAIA Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MAIA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.

How has MAIA stock performed over the past year?

MAIA Biotechnology, Inc. returned -9.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MAIA Biotechnology, Inc. do?

Maia Biotechnology Inc. is a biotechnology company primarily focused on developing and commercializing therapies to treat cancer.

What is the latest news on MAIA?

The most recent item we track (GlobeNewsWire, 17 Aug 2026): "Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)". Diamond Equity Research released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary comes from a report commissioned by MAIA Biotechnology and produced by Diamond Equity Research, a firm focused on small-cap public companies.

Company

About MAIA Biotechnology, Inc.

Maia Biotechnology Inc. is a biotechnology company primarily focused on developing and commercializing therapies to treat cancer. With an emphasis on innovative treatment approaches, the company is known for its proprietary program that targets significant oncology indications, underlining its commitment to transforming the current landscape of cancer treatment. Maia Biotechnology’s pipeline features novel therapies engineered to harness the body's immune system, aiming to offer new hope for patients where traditional treatments have proven ineffective. The biotech industry, particularly in oncology, is pivotal given the rising global cancer burden, and Maia Biotechnology is positioned at the forefront of these crucial medical advancements. By focusing on targeted therapies and addressing unmet needs in cancer care, Maia Biotechnology plays a significant role in both the healthcare sector and the broader efforts to improve patient outcomes in oncology. Through rigorous research and development, the company strives to bring innovative solutions that could potentially have a substantial impact on the quality of life for cancer patients worldwide.

CEO Dr. Vlad Vitoc M.B.A., M.D. · 13 employees · United States · https://maiabiotech.com